Aquestive Therapeutics (AQST) announced changes to its leadership team to support the launch of Anaphylm, if approved by the United Stated Food and Drug Administration, FDA, and expansion of its pipeline. Matthew Davis, M.D., RPh will join immediately as Chief Development Officer, CDO; Gary Slatko, M.D., M.B.A, will become interim Chief Medical Officer, CMO; Peter Boyd, M.B.A, has been promoted to Chief People Officer, CPO
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
- Aquestive Therapeutics Advances Anaphylm Clinical Development
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts